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ABSTRACT 
Background Many astronauts do not sleep well due to the difficult environment in 
space. Hypnotics such as temazepam or zolpidem are often taken while in space and/or 
the night prior to returning to Earth. Until now, no data have illustrated the effect of 
these sleeping medications on postflight hemodynamic responses. The purpose of this 
study was to determine if the use of different hypnotics during flight has any effect on 
cardiovascular responses to standing in astronauts upon returning to Earth's gravity. 
Methods Astronauts were separated into three groups: control group (n = 40), 
temazepam group (15 or 30 mg; n 9), and zolpidem group (5 or 10 mg; n = 8). In this 
study, temazepam and zolpidem were only taken the night before landing. The systolic 
and diastolic blood pressures and heart rates of the astronauts were measured during 
stand test before spaceflight and on landing day. 
Results Systolic blood pressure decreased and heart rate increased significantly in the 
temazepam group when compared with the control group on landing day. However, 
systolic blood pressure and heart rate were not different between zolpidem and control 
groups.
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Conclusions Temazepam may aggravate orthostatic hypotension after spaceflight. 
Zolpidem may be a better choice as a sleep aid while in space. 
Key words: astronaut, spaceflight, orthostatic hypotension, temazepam, zolpidem,
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INTRODUCTION 
Many astronauts experience difficulty sleeping during spaceflight.' Because sleep 
deprivation affects performance and can cause other medical and operational problems, 
the in-flight use of sedative-hypnotics as sleeping aids is common. 4
 Two hypnotics, 
temazepam (Restoril, a benzodiazepine) and zolpidem (Ambien, an imidazopyridine), are 
used by astronauts during their missions, including the night prior to shuttle landings. 
Some sedative-hypnotics have side effects that affect the cardiovascular system by 
decreasing arterial blood pressure and increasing heart rate. 5
 After spaceflight, astronauts 
experience orthostatic hypotension 68
 due to, among other things,- reduction of plasma 
volume and autonomic dysfunction. It is possible that the use of these hypnotics is an 
additional contributor. Temazepam belongs to the benzodiazepine family that causes 
sedation, hypnosis, decreased anxiety, muscle relaxation, anterograde amnesia, and 
anticonvulsant activity. 9 Zolpidem is an imidazopyridine that differs structurally from 
the benzodiazepines.'° It has sedative-hypnotic properties, but has only minor anxiolytic 
and anticonvulsant properties, and no myorelaxant 	 1l2 Although the National 
Aeronautics and Space Administration (NASA) began using temazepam and zolpidem as 
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inflight sleeping aids in 1990 and 1994, respectively, the ettects ot these medications on 
cardiovascular responses to upright posture have not been documented. Therefore, the 
purpose of this study was to assess whether hypnotics exacerbate orthostatic intolerance 
in astronauts on landing day.
METHODS 
This study was conducted in two parts. The first part was a prospective study in 
laboratory volunteers on the effects of temazepam on cardiovascular responses to 
standing. Based on those results, a retrospective analysis was performed on astronauts' 
preflight stand test, and postflight stand tests with and without the influence of 
temazepam or zolpidem. 
Subjects. The NASA Johnson Space Center Committee for the Protection at Human 
Subjects approved these protocols. There were two sets of subjects: astronauts and non-
astronauts. 
Ground-based Study. All subjects (non-astronauts) had passed an Air Force Class III 
physical exam before their participation and signed written informed consent. Ten
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subjects were studied before and ten hours after a single, 30 mg oral dose of temazepam. 
Subjects abstained from caffeine, alcohol, and any medications for 12 hours prior to each 
study and ate a.light breakfast before reporting to the laboratory. Testing on the first day 
began at 8 AM. After the test session, subjects were given 30 mg of temazepam which 
they ingested orally at 10 PM that night. They were studied again at 8 AM the following 
morning, ten hours after taking the drug. For each test, subjects were placed on a bed in a 
quiet, air-conditioned room where the temperature was 23-25 °C. After 20 minutes of 
supine rest, baseline arterial blood pressure and heart rate were recorded. Then a tightly 
sealing Silastic chamber, connected to a computer-controlled bellows, was strapped to the 
anterior neck.' 3 During held expiration, and triggered by successive R-waves, the 
pressure in the neck chamber was increased to +40 mmHg for four heart beats and then 
reduced to, +25, +10, -5, -20, -35, -50, and -65 mmHg, and then returned to ambient 
pressure. This sequence was repeated seven times. R-R intervals were plotted against 
carotid distending pressures (systolic blood pressure minus chamber pressure). After the 
neck suction protocol was completed, a stand test was performed. Subjects were assisted 
to a standing position by three investigators who lifted them behind both shoulders and 
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swept their feet off the bed. This helped to minimize artifactual arterial blood pressure 
changes with the effort of standing. Subjects remained standing without support for ten 
minutes unless presyncopal symptoms necessitated the termination of the test. Their 
heart rates were recorded with electrocardiogram (SpaceLabs, Redmond, WA), and 
systolic and diastolic blood pressures were measured manually with sphygmomanometer 
every minute. Finger arterial blood pressure was measured by a beat-to-beat pressure 
detector (Finapres, Ohmeda, Tewksburi, MA). 
Flight-based Study. Informed consent was obtained according to the guidelines set 
forth by the Committee for the Protection at Human Subjects at the NASA Johnson Space 
Center. The astronaut subjects were separated into three different groups: those who took 
no medication the night before landing (n = 40), those who took oral temazepam (15 or 
30 mg) the night before landing (n = 9), and those who took oral zolpidem (5 or 10 mg) 
the night before landing (n = 8). No astronaut took either medication before flight and no 
additional medications other than the hypnotics were taken before landing. This 
retrospective analysis encompasses a 7-year period from January 1990 until December 
1996. Stand tests were performed according to the same protocol described above, ten 
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uays before launch and two to four hours after landing. All preflight stand tests were 
conducted at Johnson Space Center in Houston, Texas, and landing day stand tests were 
conducted either at Kennedy Space Center, Florida, or Dryden Flight Research Center at 
Edwards Air Force Base, California. 
Data Analysis - Carotid Baroreceptor-Cardiac Reflex Response.
	 All 
electrocardiograms and neck pressures were recorded on digital tape for subsequent 
analysis. R-R intervals were measured from the electrocardiogram. Carotid-cardiac 
baroreflex responses were determined off-line using standard data acquisition and 
analysis packages. Responses to baroreflex were reduced to the following set of 
parameters for analysis: range of R-R response, maximum slope, and operational point. 
Maximum slopes were identified with linear regression analyses applied to each set of 
three consecutive data pairs on the stimulus-response relation. Operational points were 
defined as [(R-R interval at 0 mmHg neck pressure - minimum R-R interval) / (R-R 
interval range)] x 100%. The operational point is a measure of the amount of buffering 
capacity above and below baseline systolic blood pressure due to increases or decreases 
in cardiac-vagal outflow, respectively.
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Data Analysis - Stand Tests. The stand portion of the test assessed the systolic and 
diastolic blood pressures and heart rates pre- and post-temazepam and zolpidem. Both 
systolic and diastolic blood pressures and heart rates were measured every minute for six 
minutes supine and ten minutes standing. Systolic and diastolic blood pressures and heart 
rates were stable in the supine position, so only the last supine measurement was 
reported. 
Statistics. All data are presented as mean ± SE. A Kruskal-Walljs one-way analysis 
of variance (ANOVA) on Ranks was used for between groups comparison (i.e. control 
group vs. temazepam or zolpidem group). A paired t-test was used for within-group 
comparisons (i.e. pre- vs. post-temazepam). For all tests, significance was set at P < 0.05. 
RESULTS 
The anthropometric data for all subjects are presented in Table 1. Age, body weight, 
and height did not differ significantly among any of the groups. Between January 1990 
and December 1996, 13.7% of astronauts took temazepam and 4.6% took zolpidem 
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during flight. Therefore, astronauts took temazepam three times more than zolpidem 
during this period. 
Ground-based Results. In non-astronauts, one subject who had not become 
presyncopal before taking temazepam became presyncopal during standing after taking it. 
Two additional subjects reported feeling lightheaded and dizzy the morning after taking 
temazepam but before reporting to the laboratory. These two subjects did not become 
presyncopal during their stand tests. Fig. I shows that finger arterial blood pressures and 
heart rates decreased in the subject who became presyncopal after taking temazepam. 
Before temazepam (upper panel), arterial systolic blood pressure was maintained the 
entire time of standing. After temazepam, systolic blood pressure dropped to 70 mmHg 
(bottom panel) and the subject became presyncopal. Standing heart rate post-temazepam 
was 15 bpm higher than pre-temazepam until presyncope occurred. 
Fig. 2 represents supine and standing arterial blood pressures and heart rates before 
and after 30 mg of temazepam in the ground-based subjects. As a group, there was no 
effect of temazepam on supine or standing arterial blood pressures. Supine heart rates 
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were not different after temazepam, but standing heart rates were significantly higher (P 
•< 0.05). 
Carotid Baroreceptor Reflex Test. Carotid baroreceptor-cardjac reflex responses 
before and after temazepam are shown in Fig. 3 and Table 2. Temazepam resulted in no 
change in slope, range, or operational point, but caused a significant shift on the R-R 
interval axis which paralleled the increase in heart rate. 
Flight-based Results. Fig. 4 depicts supine and standing systolic and diastolic blood 
pressures and heart rates for the subjects who took temazepam the night before landing 
and those who did not. No astronaut took any drug preflight. Before flight (Fig. 4 left), 
supine and standing blood pressures and heart rates were not different between groups, 
although blood pressures were somewhat lower in the temazepam group. On landing day 
(Fig. 4 right), supine blood pressures were higher than preflight in both groups, but those 
who had taken temazepam had very dramatic falls in systolic blood pressure with 
standing that were significantly greater than in those who had not taken the drug (P < 
0.05). There were no intergroup differences in supine or standing heart rates before 
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flight, however on landing day, the temazepam group had significantly higher standing 
heart rates than those who did not take the drug. 
Fig. 5 depicts supine and standing systolic and diastolic blood pressures and heart 
rates preflight and postflight in the control group of astronauts versus those who took 
zolpidem the night before landing. Unlike the temazepam data, there were no intergroup 
differences in supine or standing values either preflight or postflight. 
DISCUSSION 
This study was initially undertaken because 14% of astronauts were taking in-flight 
sleeping medications 4
, and it was unknown what effects this practice had on arterial 
pressure control. The most important finding from this study is that astronauts who took 
temazepam as a sleeping aid the night before landing had significantly lower standing 
systolic blood pressures after landing than those who did not. This finding was not 
reproduced in astronauts who took zolpidem the night before landing. It also was not 
reproduced in subjects who did not fly in space. These results suggest that the use of 
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-1zepam as an in-flight sleeping aid has contributed significantly to the high incidence 
of post-spaceflight orthostatic hypotension in returning astronauts. 
The most apparent difference between the two drugs studied is the half-life. The half-
life of temazepam is 11 - 20 hours and the half-life of zolpidem is 1.5 - 4 hours.'4 
Therefore, zolpidem is probably eliminated by the time of landing. In addition, there also 
are differences in the mechanisms of actions between the two drugs. 
In the initial study, the ground-based subjects did not, as a group, experience low 
blood pressure during standing after temazeparn, but they did have significantly higher 
standing heart rates. These findings were not unexpected. Several studies have shown 
that temazepam does not affect arterial blood pressure, yet can cause significant increases 
in heart rate during sitting, 5
 standing5
 and lower body negative pressure' 5
. However, one 
subject did become presyncopal after taking temazepam, and two additional subjects 
reported incidents of dizziness and hypotension after taking the drug. 
In the retrospective analysis of the astronaut stand tests, temazepam was associated 
with significant falls in standing systolic blood pressure after spaceflight (Fig. 4). In fact, 
their hemodynamic responses to upright posture fell within the range of clinical 
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orthostatic hypotension: systolic blood pressure falls greater than 20 mmHg and/or heart 
rate increases greater than 27 beats per minute 6
 Thus, it is clear that temazepam has 
hemodynamic effects which are significantly exaggerated when combined with the 
effects of spaceflight itself. 
Temazepam, a benzodiazepine, binds non-selectively to all three subtypes of the 
benzodiazepine receptor (BZ1, BZ2, and BZ3). Thus, in addition to BZ1 sedative effects, 
benzodiazepine also has BZ2, and BZ3's anticonvulsant, myorelaxant, and anxiolytic 
effects.' 4
 The muscle relaxant properties probably enhance venous pooling during 
upright posture. This normally does not result in systolic blood pressure falls because 
baroreflex-mediated increases in heart rate maintain cardiac output. This idea is 
supported by the present finding that carotid baroreceptor-cardjac reflex is intact after 
temazepam. However, in individuals who are hemodynamically compromised, such as 
the elderly' 7 ' 9
 temazepam can cause significant falls in systolic blood pressure. 20
 We 
suggest that returning astronauts are affected by temazepam because they are already 
compromised by reduced plasma volume, 8
 autonomic dysfunction, 2 ' increased leg 
compliance, 22
 and skeletal muscle atrophy.23'24
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Unlike temazepam, zolpidem had no effect on arterial blood pressure and heart rate 
responses to standing after spaceflight. Zolpidem is not a benzodiazepine, but an 
imidazopyridine, which only selectively binds the BZ1 benzodiazepine receptor subtype. 
Thus it does not have BZ2 and BZ3 myorelaxant properties 2527
 and is not likely to 
aggravate venous pooling.' 0'28 '29
 Zolpidem rarely causes cardiovascular effects such as 
hypotension or tachycardia 3.° even in elderly 
In summary, we compared hemodynamic side effects of two kinds of sleeping 
medications that are routinely taken by astronauts the night before landing. On landing 
day, temazepam clearly caused orthostatic hypotension. Zolpidem had no such effect. 
Thus, temazepam should not be the initial choice as a sleeping aid for astronauts the night 
before landing. Instead, zolpidem may be a first choice when choosing sedative-
hypnotics for use in space.
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FIGURE LEGENDS 
Fig. 1. Finger arterial blood pressure and heart rate (black line) in one subject during 
stand tests before (top panel) and ten hours after (bottom panel) temazepam. Note the 
presyncopal episode in the bottom panel. 
Fig. 2. Systolic (SBP, top panel) and diastolic blood pressures (DBP, center panel) 
and heart rates (HR, beats per minute bpm, bottom panel) pre- (open triangle) and post-
temazepam (closed triangle) during stand tests in ground-based subjects (non-astronauts). 
Each value shows mean ± SE. * P <0.05 vs. pre-temazepam. 
Fig. 3. Average R-R interval responses to ramped neck pressure-suction in pre- (open 
circle) and post-temazepam (closed circle) administration in groud-based subjects (non-
astronauts). The open and closed triangle symbols represent the R-R intervals of pre- and 
post-temazepam group at 0 mmHg neck pressure, respectively. Each value shows mean 
± SE. 
Fig. 4. Systolic (SBP, top panel) and diastolic blood pressures (DBP, center panel) 
and heart rates (HR, beats per minute bpm, bottom panel) of astronauts preflight (left 
panel) and on landing day (right panel). Preflight, astronauts in both control (open circle) 
23
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and temazepam (open triangle) groups did not take any medication. On landing day, 
astronauts in the control group (closed circle) did not take any drug, but in the temazepam 
group (closed triangle) took 15 or 30 mg of temazepam. Each value shows mean ± SE. 
*D < 0.05 vs. control group,
	 < 0.01 vs. control group. 
Fig: 5. Systolic (SBP, top panel) and diastolic blood pressures (DBP, center panel) 
and heart rates (HR, beats per minute = bpm, bottom panel) of astronauts preflight (left 
panel) and on landing day (right panel). In preflight, astronauts in both control (open 
circle) and zolpidem (open triangle) groups did not take any medication. On landing day, 
astronauts in the control group (closed circle) did not take any drug, but in the zolpidem 
group (closed triangle) took 5 or 10 mg of zolpidem. Each value shows mean ± SE. 
There were no differences between zolpidem and control groups.
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during stand tests before (top panel) and ten hours after (bottom panel) temazepam. Note 
the presyncopal episode in the bottom panel.
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Table 1. Age, body weight and height in different groups of non-astronauts and astronauts 
(Pre- & Post-Temazepam) (M'6, F=4) (30-50) (64- 81) (152- 188) 
Astronauts 
(Control Group)
40 42.0±0.7 76.8± 1.8 178.7± 1.8 (M=37, F=3) (33 - 50) (46 - 99) (160 - 193) 
Astronauts 
(Temazepam Group)
9 
(M=8, F1)
44.7±2.0 76.8±2.0 176.8±2.6 
(35 - 51) (68 - 84) (173 - 185) 
Astronauts 8 42.4±2.4 80.5±3.9 182.0±2.8
of age, body weight, and height.
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Table 2. Descriptors of carotid baroreflex function 
Measurement	 Pre-Temazepam
	 Post-Temazepam 
iiiici vai iiisec
	 980 ± 70
	 923 ± 65 
Maximum R-R interval (msec)
	 11 89 ± 93
	 1110 ± 65 
Pressure at maximum R-R interval (mmHg)
	 1 59 ± 3
	 172 ± 3 
Operational point (%)
	 41 ± 9	 36 ± 5 
Maximum slope (msec/mmHg)
	 5.3 ± 0.7	 4.7 ± 0.7 
Response range (msec)
	 236 ± 44	 223 ± 29 
The values are from two curves of R-R interval with carotid distending pressure in Fig.2 
(means ± SE).
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